Hold JNJ; add on supported pullback to $261–264 or breakout above $276.47 on 7M+ shares
Maintain current JNJ allocation; do not add at $273.41. For new capital, deploy 1–1.5% on a supported $261–264 pullback (or 1% after close above $276.47 on 7M+ shares), keeping total new exposure at 2–3%. Reassess tactically on close below $253.59 50 SMA; exit if $227 is breached. Upgrade to Overweight on RSI below 55 with volume confirmation or stabilized forward EPS; move to Underweight on worse-than-expected Stelara erosion, talc verdict exceeding $1B, or PEG rising above 5.0x.
| Position | Action |
|---|---|
| Maximum new exposure | 2–3% of portfolio |
| Tactical warning | Close below $253.59 50 SMA |
| Catastrophic structural stop | $227 |
JNJ is actively re-rating higher as the Stelara LOE headwind fades, revealing a double-digit compounding business underpinned by a 64-year dividend streak, 25.7% ROE, and a macro regime explicitly favoring quality duration plays — making any pullback a core-positioning opportunity.
| Indicator | Value | Signal |
|---|---|---|
| Price (Close) | 273.41 | bullish |
| Open | 272.99 | neutral |
| High | 276.47 | bullish |
| Low | 270.56 | neutral |
| Volume | 6.26M | neutral |
| 10 EMA | 264.27 | bullish |
| 50 SMA | 253.59 | bullish |
| 200 SMA | 229.57 | bullish |
| RSI (14) | 68.59 | bullish |
| MACD Line | +3.89 | bullish |
| MACD Signal | +3.02 | bullish |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Close above $276.47 on at least 7M shares
Then: Deploy 1% tranche
Stelara biosimilar drag is fading, not expanding; Tremfya is offsetting
· concedes: PEG of 4.56x and forward PE of 22.2x appear elevated vs. high-growth comps like Lilly; Stelara biosimilar headwind is real (though fading); Talc litigation remains a known, settling tail risk; +19% above 200 SMA represents near-term extension risk (though 200 SMA is rising)
JNJ at $273 is a trap for new buyers: premium multiples on a 6.6% top-line grower with stretched technicals, unresolved litigation risk, and a goodwill balance that represents nearly half the balance sheet.
· concedes: JNJ is a long-term quality franchise worth owning — the dividend is a real asset for income-focused investors; The 64-year dividend streak is genuinely impressive even if it constrains flexibility; Diversification provides some downside protection; ROE of 25.7% is genuinely high even if mechanically boosted by buybacks
→ vs conservative: Over-weighting possible mean reversion (22.2x P/E, 4.56 PEG) while under-weighting earnings normalization, trend acceleration, MedTech innovation, and defensive macro positioning; TTM EPS $8.62 is depressed by unusual items, not representative of sustainable earnings; conservative case effectively requires assuming litigation charges return and forward guidance fails
→ vs neutral: Anchoring on exact $255–$260 entry price risks missing the move if breakout continues through $280; waiting for convergence may never result in adding position given rising MAs; 10 EMA and Bollinger middle band are rising so convergence is not guaranteed
| MACD Histogram | +0.87 | bullish |
| Bollinger Middle Band | 261.40 | bullish |
| Bollinger Upper Band | 271.71 | bullish |
| Bollinger Lower Band | 251.09 | neutral |
| ATR (14) | 5.87 | neutral |
| Distance Above 200 SMA | +19.1% | neutral |
| Distance Above 50 SMA | +3.9% | neutral |
| Distance Above 10 EMA | +3.5% | neutral |
| 30-Day Rally | +10.7% | bullish |
| Daily Change (08-18 to 08-19) | +2.85% | bullish |
Support: 229 · 251.09 · 253.59 · 258 · 260 · 261.4 · 264.27 · 270.56 | Resistance: 271.71 · 276.47 · 280
JNJ is in a confirmed, accelerating uptrend as of 2026-08-19. All three moving averages are stacked bullishly (10 EMA 264.27 > 50 SMA 253.59 > 200 SMA 229.57), MACD histogram is positive and expanding at +0.87, and price broke above the upper Bollinger Band at 271.71 on a strong +2.85% session. RSI at 68.59 is strong but not yet at the overbought 70 threshold. Primary risk is short-term extension given price is +19.1% above the 200 SMA; a snap-back inside the upper band would warrant defensive action. Preferred strategy is to buy pullbacks toward 264 (10 EMA) or 261 (Bollinger mid) with stops below 258.
Market Cap
$658.89B
PE Ratio (TTM)
31.72x
Forward PE
22.21x
PEG Ratio
4.56
Price to Book
7.75x
EPS (TTM)
$8.62
Forward EPS
$12.31
Beta
0.231
52-Week High
$276.47
52-Week Low
$173.33
50-Day Avg
$252.76
200-Day Avg
$230.58
Revenue (TTM)
$97.93B
EBITDA (TTM)
$34.87B
Net Income (TTM)
$21.04B
Gross Margin
68.1%
Operating Margin
29.2%
Net Margin
21.5%
ROE
25.7%
ROA
8.6%
Total Assets
$201.06B
Stockholders' Equity
$84.97B
Total Debt
$49.04B
Cash & Equivalents
$20.76B
Net Debt
$28.61B
Debt/Equity
0.577
Current Ratio
1.089
Book Value/Share
$35.28
Operating CF (TTM)
$27.6B
FCF (TTM)
$16.89B
Dividend (Annual)
$12.6B
Dividend Yield
3.1%
Payout Ratio
60%
YoY Revenue Growth (Q2'26)
+6.6%
Goodwill & Intangibles
$96.71B
Strengths
Concerns
Johnson & Johnson is a diversified healthcare conglomerate (~$658.89B market cap) operating Innovative Medicine (pharmaceuticals) and MedTech (medical devices) segments. Q2'26 results show revenue of $25.31B (+6.6% YoY) with EPS of $2.27, and TTM metrics include $97.93B revenue, 25.7% ROE, and $16.89B FCF. The company carries $96.71B in goodwill/intangibles (48% of assets), $49.04B total debt against $20.76B cash, and maintains a 3.1% dividend yield with 60% payout ratio. Key risks include Stelara patent expiration, elevated valuation (PEG 4.56x), and talc litigation overhang, while opportunities center on the Caplyta acquisition and pipeline catalysts. Trading bias: Long-term HOLD with tactical BUY on weakness toward 200-day MA (~$230).
Macro: The macro backdrop is unusually supportive for high-quality dividend-payer pharma. Prediction markets show 85% probability of no Fed rate cuts in 2026, 8% US recession probability, 9% UK recession probability, and 31% Japan recession probability. The US Treasury expanded long-bond buybacks, pushing long-term yields down (bull steepening) while short-term yields held firm. Healthcare/biopharma is outperforming the broader tape on rotation, with risk tone described as cautious-constructive.